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Abstract
Aim—We studied the use of methyl-CpG binding domain (MBD) protein-enriched genome
sequencing (MBD-seq) as a cost-effective screening tool for methylome-wide association studies
(MWAS).
Materials & methods—Because MBD-seq has not yet been applied on a large scale, we first
developed and tested a pipeline for data processing using 1500 schizophrenia cases and controls
plus 75 technical replicates with an average of 68 million reads per sample. This involved the use
of technical replicates to optimize quality control for multi- and duplicate-reads, an in silico
experiment to identify CpGs in loci with alignment problems, CpG coverage calculations based on
multiparametric estimates of the fragment size distribution, a two-stage adaptive algorithm to
combine data from correlated adjacent CpG sites, principal component analyses to control for
confounders and new software tailored to handle the large data set.
Results—We replicated MWAS findings in independent samples using a different technology
that provided single base resolution. In an MWAS of age-related methylation changes, one of our
top findings was a previously reported robust association involving GRIA2. Our results also
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suggested that owing to the many confounding effects, a considerable challenge in MWAS is to
identify those effects that are informative about disease processes.
Conclusion—This study showed the potential of MBD-seq as a cost-effective tool in large-scale
disease studies.
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Epigenetic modifications to chromatin provide stability and diversity to the cellular
phenotype. These modifications are largely preserved or regenerated during cell division
[1,2]. Among the different forms of epigenetic modifications, the most intensively studied is
the methylation of DNA cytosine residues at the carbon 5 position. This common epigenetic
mark is most often, although not exclusively, found in the sequence context CpG and is
typically associated with transcriptional repression.
Methylation studies are a promising complement to genetic studies of variation in DNA
sequence and structure. First, because methylation directly affects gene expression, it may
capture additional individual variation in disease susceptibility [3]. Indeed, dysregulation of
DNA methylation has been associated with a wide variety of human diseases, including
neurological disorders such as Alzheimer’s and Parkinson’s diseases [4], autoimmune
disorders such as systemic lupus erythematosus [5], cardiovascular disease [6] and several
types of cancer [7–9]. Second, methylation can account for a wide variety of phenomena
that characterize complex diseases [8,10] such as sex differences [11,12], genotype–
environment interactions [13,14], and age-related patterns associated with the disease course
[15]. Third, methylation sites are potential new drug targets as they are modifiable by
pharmaceutical interventions [16] and have good properties from a translational perspective
such as being stable and enabling cost-effective assays in biosamples that can be relatively
easy to collect [17].
The potential importance of DNA methylation in the etiology of complex diseases has led to
interest in the development of methylome-wide association studies (MWAS; as our study
only considers methylation and not histone modification and other epigenetic marks, it is not
an epigenome-wide association study) [1,18] aimed at interrogating all possible methylation
sites in the human genome [19]. The most comprehensive laboratory method for
ascertaining methylation (DNA cytosine residues at the carbon 5 position) status at each
nucleotide position is bisulfite sequencing [20], where unmethylated cytosines in genomic
DNA are converted to uracil and then converted to thymine in post-bisulfite PCR [21]. This
single base resolution is attractive because it allows precise mapping of disease relevant sites
[22]. However, owing to the combination of high costs of sequencing entire genomes and
the large numbers of samples needed to provide adequate statistical power, whole-genome
bisulfite sequencing is not currently economically feasible as a screening tool for disease
association studies [18]. An alternative is reduced representation bisulfite sequencing that
applies bisulfite sequencing to a reduced portion of the genome. It captures approximately
12% of all CpGs [23] that tend to be located in CpG dense regions [24].
Other methods have been developed that differentiate methylation status using enzymatic
digestion or affinity-based capture methods, followed by detection on arrays or using next-
generation sequencing (NGS). Examples of array-based methods include the Infinium
system from Illumina (CA, USA) [19], but even their largest array interrogates only 450,000
loci. Genome-wide tiling arrays such as the 2.1 million probe array set from NimbleGen
(WI, USA) or the 45 million probe array set from Affymetrix (CA, USA) [25] offer more
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comprehensive coverage. However, NGS seems more promising than tiling arrays [18,26].
Not only can NGS, in principle, detect all methylation sites in the human genome, the
relatively lower amount of starting material also reduces the need for extensive DNA
amplification and hence errors and bias. Furthermore, the increasing data volume generated
per run, the decrease in reagent costs and fast semi-automated sample preparation have
already made NGS a very competitive option in terms of cost per measured site.
Methods for detection of methylation that are adaptable to NGS include HpaII tiny fragment
enrichment by ligation-mediated PCR (HELP) that uses the methylation sensitive enzyme
HpaII [27], methylated DNA immunoprecipitation (MeDIP) that uses an antibody for 5-
methylcytosine [28], and methyl-CpG binding domain (MBD)-based capture that uses the
methyl binding domain of methyl binding proteins MBD2 or MBD3L1 to capture
methylated DNA fragments [26]. Ultimately, enzyme-based methods are restricted by the
need for a specific recognition sequence, meaning they can never be unbiased and
representative of the whole genome. The affinity-based capture methods, while lacking the
single base resolution of bisulfite sequencing, arguably provide a good compromise. Among
affinity-based capture methods, there are differences in assay properties depending on the
DNA binding protein/antibody used. Both MeDIP sequencing and MBD-isolated DNA
sequencing (MBD-seq) are capable of detecting differentially methylated regions (DMRs)
[29] and capture approximately the same proportions of the methylome [23]. However,
whereas the proteins used for MBD-based capture strictly bind to methylated CpGs, the
antibody used in MeDIP captures DNA fragments containing any methylated C. Non-CpG
methylation may be of great importance for complex diseases. However, taking association
studies of sequence variants as an example, the different polymorphisms (e.g., common
SNPs, rare SNPs and CNVs) are typically not examined in a single study as different study
designs and techniques are more suitable for some polymorphisms than for others. Similar
arguments may apply here. For example rather than simply calculating the number of reads
covering a CpG to quantify methylation, the use of peak finding algorithms may be
considered for MeDIP and it could also be the case that there may be more rare methylation
sites requiring different kinds of association tests. Furthermore, because sporadically
methylated sequences can comprise a significant portion of the data generated by MeDIP
[26], (many) more reads may be needed to accurately measure all methylation signals. To
some extent, we view MBD-seq as being similar to genome-wide association study (GWAS)
with common SNPs as a first pass at examining the methylome by only considering sites
where methylation is likely to occur. Perhaps this more focused technology may be one of
the factors contributing to the observation that MBD-seq may detect substantially more
DMRs compared with MeDIP-seq [30].
MBD-seq has already been demonstrated to be highly specific, sensitive and applicable to
identifying DMRs [23,26,29,31,32]. Laboratory automation can facilitate MBD-seq on a
large scale. However, because MBD-seq has not yet been applied on a large scale, an
efficient and accurate pipeline for data processing and analysis that capitalizes on the
inherent strengths of the approach is currently not available. The purpose of this article is to
study the potential of MBD-seq for large-scale MWAS and develop a robust pipeline for
analysis. For this purpose we will make use of a schizophrenia case–control data set where
an average of 68 million reads were sequenced in 1500 individuals, amounting to over 100
billion reads.
Materials & methods
Figure 1 gives an overview of the ‘Materials & methods’ section of this paper by
summarizing the data analysis pipeline plus key results from each step. Full details can be
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found in the Supplementary Material (see www.futuremedicine.com/doi/suppl/10.2217/epi.
12.59).
Sample description
Our study includes 750 schizophrenia cases and 750 controls, as well as 75 technical
duplicates. This study is part of a large ongoing project entitled ‘A Large-Scale
Schizophrenia Association Study in Sweden’. The project is supported by grants from
National Institute of Mental Health (NIMH) and the Stanley Foundation and aims at
improving our understanding of the etiology of schizophrenia and bipolar disorder plus their
clinical and epidemiological correlates using high dimensional biological investigations and
proper analysis. For details on the project see [33–35]. Cases with schizophrenia were
identified via the Swedish Hospital Discharge Register. Population controls, who had never
received a discharge diagnosis of schizophrenia, were selected at random from the national
population registers and then group matched to the cases on age, gender and county of
residence. All procedures were approved by ethical committees in Sweden and in the USA,
and all subjects provided written informed consent (or legal guardian consent and subject
assent). DNA was extracted from peripheral blood donated at the local medical facilities of
the participants. Samples were then shipped to the Broad Institute where they were
fingerprinted using a 24-plex fingerprint iPLEX assay (Sequenom, CA, USA) prior to
shipping to the service provider that did the sequencing for this project.
Laboratory procedures
We used the MethylMiner™ kit from Invitrogen (CA, USA) that employs MBD protein-
based enrichment of the methylated DNA fraction, followed by single end sequencing (50
bp read length) on the Applied Biosystems SOLiD next-generation sequencing platform
(Life Technologies, CA, USA). Methods were standard and based upon manufacturer’s
recommendations (see Supplementary Material). Genomic regions that are CpG poor can be
difficult to capture by MBD-seq [30]. To improve methylome- wide coverage, we used an
existing protocol variant that increases the relative number of fragments from CpG poor
regions by eluting the captured methylated fraction with 0.5 M NaCl.
For replication purposes we used targeted pyrosequencing (Qiagen, CA, USA). This
quantitative method allows for targeted sequencing of bisulfite converted DNA with high
accuracy. We included several controls to ensure the assays worked properly (e.g., a
standard curve of five DNA samples in duplicates with known methylation levels).
Furthermore, each additional set of study samples (e.g., each additional 96-well plate)
contains two plate controls, in duplicates, of DNA from the standard curve. Assay designs
and further details are available in the Supplementary Material.
Data analysis
Alignment—The sequenced reads were aligned to the human genome (build hg19/
GRCh37) using BioScope 1.2 (Life Technologies) that aligns in color– space and takes full
advantage of the increased ability of SOLiD two-base encoding to identify sequencing errors
[36]. We used a seed-and-extend approach combined with local alignment and multiple
schemas. Specifically, our seed was 25 bases. Rather than considering the entire extension,
local alignment may improve sensitivity by finding the maximum similarity score between
the reference sequence and a substring of the extension. A maximum of two color space
mismatches were allowed in the seed (e.g., as two color call matches are required to change
the base call, a SNP will have two color call mismatches). If the seed could not be mapped, a
second schema was attempted by moving the seed from base 1 to base 15.
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Coverage estimation—In the case of MBD-seq, only fragments with methylated CpGs
can be pulled down. Given that we know exactly where the CpGs are located, there is no
need to search for peaks and to obtain a methylation measurement. We therefore calculated
coverage for the 28,217,444 CpG sites in the reference genome (hg19/GRCh37). A standard
procedure is to count the number of sequence reads covering the CpG. Because the
methylation of any CpG in the entire fragment could lead to its capture by the MBD protein
binding, the read length is sometimes extended to the expected fragment length. However,
because not all fragments will have exactly the same specified size and the fragment pool
obtained after shearing may not be identical to the pool that gets successfully sequenced
(e.g., smaller fragments may be more likely to get pulled down by the enrichment protocol),
this procedure can be imprecise. Furthermore, particularly in large-scale studies there may
be (stochastic) variation in the fragment size distribution across samples. Thus, rather than
assuming an identical predetermined fragment size for all fragments and samples, we
estimated the fragment size distribution for each sample from the empirical sequencing data.
A limitation of commonly used methods for estimating fragment size distributions, for
example those used in ChIP-seq peak finding algorithms [37,38], is that they make strong
parametric assumptions about these distributions and do not take advantage of the specific
features of MBD-seq data where we know exactly where methylation can occur. We
therefore developed a nonparametric method that uses isolated CpGs (no other CpG site
within 400 bp) to estimate the fragment size distribution empirically from the sequencing
data. To validate our method we performed extensive simulations and sequenced paired-end
libraries in eight mice [Van den Oord E, Bukszar J, Rudolf G et al. Estimation of CpG
coverage in whole methylome next-generation sequencing studies (2012), Submitted]. Using
the successfully aligned read pairs, we obtained the ‘observed’ fragment size distribution by
subtracting the start positions of the two reads. We then performed coverage calculations
using the fragment size distributions as observed in paired-end read data. Next we
performed a ‘traditional’ coverage calculation where we counted the number of sequence
reads covering the CpGs. Results showed that the mean coverage was merely 29.2% of that
obtained after analyzing the paired-end data. Furthermore, when we correlated these
coverage estimates with those obtained from the paired-end data, we only obtained a very
modest Pearson correlation of 0.606. The DNA samples were fragmented by ultrasonication
(Covaris, MA, USA) to a target median size of 150 bp. We also performed coverage
calculations by extending the read length from 50 bp to this 150 bp target. Results improved
but coverage was still underestimated by 13% and the correlation with paired-end coverage
estimates was 0.934. Finally, we excluded one read from each pair and used our estimator.
Results were now very similar to those obtained with the paired-end data with only a slight
coverage overestimation of 0.6%. In addition, our coverage estimates correlated 0.999 with
those from the paired-end data suggesting almost identical results.
The sample-specific estimated fragment size distributions were used to calculate a
probability test for each read. This probability indicates how likely it is that the fragment,
tagged by the read, covers the CpG under consideration. Coverage for each CpG can then be
calculated by taking the sum of the probabilities that all fragments in its neighborhood cover
the CpG. For example, this probability equals 1.0 for fragments with reads starting within 50
bp of the CpG, but will be ≤1.0 for fragments with reads starting further away. Coverage is
affected by the total number of used reads per sample that is a function of the laboratory
protocol (e.g., sequencer output and degree of multiplexing) rather than methylation. Our
estimates were therefore standardized using the total number of reads that remained after
quality control (QC).
When using methylation enrichment based approaches such as M BD-seq, the number of
fragments covering a particular CpG depends not only on the methylation status of that site
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but also the number of methylated CpGs in the region [23]. To make coverage estimates
more comparable across sites and improve the correlation with actual methylation levels,
coverage estimates can be further normalized using the local CpG density as a proxy for the
number of methylated CpGs in the region [39,40]. However, in association analyses we
essentially compare the means of cases and controls. As this mean difference remains
unchanged by corrections based on CpG density (i.e., the same constant will be added for
cases and controls), for sake of simplicity we did not use such a normalization step.
Duplicate- & multi-reads—Many reads map to multiple locations of the genome. Often a
single alignment can be selected because it is clearly better than the others. In the case of
multireads, multiple alignments are about equally good. Selecting only the single best
alignment for each multiread carries along the danger of alignment errors (e.g., alignments
to regions with SNPs are less likely to be best alignments because SNPs cause mismatches).
On the other hand, excluding all multireads may affect accuracy in a negative way [41].
Duplicate-reads are reads that start at the same nucleotide positions. When sequencing a
whole genome duplicate-reads often arise from template preparation or amplification
artifacts. In our context of sequencing an enriched genomic fraction, duplicate-reads are
increasingly likely to occur by chance because reads are expected to align to a much smaller
fraction of the genome.
We examined empirically whether it would be better to allow for high-quality multi- and
duplicate-reads or to exclude all such reads. To compare these strategies we calculated
Pearson correlations between the technical replicates using the data from all CpG sites. As
this correlation decreases when measurement error increases, it reflects the precision of
coverage estimates. To select high-quality multireads, any read that mapped to more than ten
loci was excluded from further consideration. From the remaining multireads, we selected
only those that aligned almost equally well to a few number of loci. Specifically, we selected
the multireads that had fewer than five alignments with alignment scores (read length – 3 ×
the number of mismatches) within five points of the best score. Multireads were weighted
proportional to the number of alignments. This essentially accounts for the uncertainty of
not knowing which part of the genome the multiread comes from by using a simple
probability estimate that the read aligns to that specific location. Thus, multireads were
treated in a different way than reads with a single best alignment in the coverage
calculations.
In all instances where >3 (duplicate) reads started at the same position, we reset the read
count to one for the coverage calculations assuming that these reads all tagged a single
fragment. If two or three reads started at the same position, we looked for other reads in the
region of ±25 bp. If other reads mapped to this area, we retained the read count of two or
three in the coverage calculations assuming that the duplicate-reads occurred by chance
owing to enrichment of fragments caused by methylated CpG in the region. If no other reads
were found, we assumed again that the duplicate reads were artifacts and reset the read
count to one for the coverage calculations.
Eliminating sites affected by alignment problems—CpG sites in loci that are
problematic in terms of alignment need to be eliminated prior to analysis as coverage
estimates will be confounded with alignment errors. For example, repetitive elements
constitute approximately 45% of the human genome. Reads may be difficult to align to these
loci because of their high sequence similarity. To identify problematic sites, we conducted
an in silico experiment. We first generated all 2.86 billion possible 50 bp single-end reads
for the human reference genome (build hg19/GRCh37), with each 50 bp sequence starting 1
bp downstream of the previous sequence. For example, the sequence of in silico read one
was identical to the sequence of positions 1–50 on chromosome 1 of the reference, read two
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was identical to positions 2–51 and so on. In the perfect scenario, aligning these reads to the
reference genome should show that each CpG is covered by 50 reads. CpG sites with
coverage <40 or >60 were eliminated from further analyses.
Data reduction—We combined highly intercorrelated coverage estimates at adjacent CpG
sites into a single mean coverage estimate. The sum of substantially intercorrelated
measurements is a more reliable indicator of the underlying signal than the individual
measurements separately [42]. Furthermore, reducing the total number of sites has
computational and statistical advantages (e.g., decreased risk of false discoveries). Rather
than using a sliding window of a predetermined fixed length, sites were combined
adaptively based on the observed Pearson correlations between them [25]. In MBD-seq
intercorrelations occur because neighboring CpGs are largely covered by the same 100–200
bp fragments, and because of biological phenomena [43]. To account for these different
causes, we used a two-stage algorithm. We first combined CpGs that were largely covered
by the same fragments by specifying a very high threshold for the intercorrelations of r >
0.9. We then used the combined ‘block’ data from the first stage using a somewhat smaller
intercorrelation of r > 0.6 to capture ‘biological’ correlations. We evaluated the robustness
of the algorithm we used to create blocks. In these studies we randomly deleted 5, 10, 25
and 50% of the CpGs and compared these results with those obtained using the complete
data. Block structures were very similar suggesting this algorithm was robust.
Case–control association testing—We used the block data obtained after the data
reduction stage as input for multiple regression analyses to test for association with case–
control status. Blocks with low coverage were excluded to minimize the probability of
analyzing regions that were not methylated and therefore would produce false-positive
MWAS findings. To identify such sites, we calculated baseline noise level in our data by
selecting sites in the genome that were at least 400 bp away from the nearest CpG. The 99th
percentile of the coverage estimated at these non-CpGs was used as a threshold below which
we declare a site as having low coverage. In addition to sex and age, to eliminate possible
assay related artifacts, we regressed out variables such as amount of starting material for
MethylMiner, the quantity of methylation-enriched DNA captured and sample batch. We
also considered ancestry as a possible covariate. These ancestral dimensions were calculated
using the multidimensional scaling (MDS) implemented in PLINK [44] with genome-wide
SNP data as input (Affymetrix 5.0 and Affymetrix 6.0 arrays, see [33] for details). Two
dimensions (MDS1 and MDS2) were sufficient to characterize the ancestral structure in this
sample. As SNP data was missing for 20% of the sample and their use as covariates would
reduce sample size and statistical power, we examined whether their inclusion was critical
by studying their correlations with methylation patterns.
Controlling for confounders to avoid false-positive findings presents a major challenge in
MWAS. In addition to technical factors associated with processing samples and the risk of
false positives due to population structure, in MWAS there are many possible differences
between cases and controls that may affect the methylome and consequently produce
significant association results. Examples include differences in lifestyle, diet and medication
use. Although these effects represent real differences between cases and controls, they are
not informative about the underlying disease processes. If assessed, such variables can be
regressed out. However, the list of potential confounders is long, only a subset of these
variables will have been measured, and many confounders may simply be unknown.
Statistical methods that first capture the major sources of variation in the methylome, and
then regress out these components when performing the MWAS may provide an effective
solution for handling confounders. We choose principle component analysis (PCA) for this
purpose because it is well developed and commonly used in high-dimensional biological
investigations [45,46]. To validate the PCA [Chen W, Gao G, Aberg K et al. Methyl-PCA: a
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toolkit for principal component analysis in methylome-wide association studies (2012),
Submitted] we simulated MWAS data for 500 cases and 500 controls with five confounding
factors. After regressing out principal components (PCs), the inflation factor λ (i.e., the
observed median test statistic value divided by the expected median assuming no effect for
any site), dropped from 8.93 to 1.01. This indicated that the PCA accurately controlled for
confounders. The same assay-related variables that were included in the MWAS were also
regressed out here to ensure that PCA captured a distinct set of confounders.
Software
We have experienced several problems when attempting to analyze the MBD-seq data using
existing software packages. First, existing packages tend to store all data in working
memory. Because of the size of the data sets (i.e., 30 million CpGs × 1500 subjects) this
becomes problematic. Second, because multiple steps of the analyses involve processing
data from all CpG sites, central processing unit time may be prohibitive. Finally, in our data
there are many more variables (i.e., sites) than samples. Consequently, standard algorithms
for performing PCA are no longer suitable. To address the above challenges we developed
two packages called COVERAGE and Methyl-PCA. Whereas COVERAGE is specific for
MBD-seq, Methyl-PCA can be used with any MWAS technology. The source code,
Windows plus Linux executables and documentation are freely available online [101].
All computational and input/output intensive parts in these two packages were implemented
in C++ where the R package was used for other purposes such as plotting and to provide a
user interface. Where relevant, the code avoids reading all data points into working memory
by processing the raw data one CpG at the time. For clusters there is the option to speed up
calculations by processing data from different chromosomes simultaneously or partition data
in subsets so that computations can be done in parallel. Statistics that are used repeatedly
(e.g., the mean across the entire sample) are calculated only once and stored to further
increase efficiency. Finally, following Gower the PCA is performed through eigen-
decomposition of a much smaller transposed variant of the data matrix [47]. All programs
(parts) were double coded either by a different programmer or in another language. For
example, to check our PCA implementation, we simulated a small methylation data set that
was analyzed with Methyl-PCA as well as the R function prcomp() that performs PCA on a
regular observed covariance/correlation matrix. Results were identical.
Bioinformatics
To annotate results we downloaded or calculated a variety of CpG features using data from
the UCSC genome browser [102]. Features included: CpG islands, shores (2000 bp flanking
a CpG island [24]), transcription factor binding sites, within gene boundaries, exon, intron or
untranslated regions, within potential gene promoters (8000 bp upstream from known
transcription start), within evolutionarily conserved regions or within regions overlapping
with known repetitive elements (RepeatMasker).
Results
Based on observations that 30–60 million reads per sample may be sufficient to reveal
valuable information for whole-genome methylation analysis [30,40], we aimed for more
than 60 million reads per sample with a minimum of 40 million reads for each of the 1575
methylomes sequenced in this investigation. The 205 samples for which we got fewer than
40 million reads were rerun to supplement reads. After these reruns only 25 samples still had
fewer than 40 million reads. The SOLiD system essentially reads each base twice thereby
producing two ‘color calls’ for each base. We deleted all reads with >2 missing color calls
after which we observed an average of 68.0 million (standard deviation [SD]: 26.8 million)
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reads per sample (see Supplementary Figure 1 for box and whisker plot). The mean quality
value (quality value: −10log10(p), with p being the probability of an error) per color call was
21.4 (SD: 1.1). Assuming these estimates are accurate, the probability of an incorrect color
call would be 0.72%. Because it takes two wrong adjacent color calls to make a base call
error, the risk of a wrong base call is predicted to be approximately 1 in 20,000 (= 0.72 ×
0.72%).
Starting with an average of 68 million reads and 1500 samples, we first dropped all reads
from runs with <40% alignment or that produced a very small number of reads. These
involved mainly reruns. The percentage of mapped reads in the remaining samples was
69.9% (SD: 6.3). Of these mapped reads, we eliminated 32.5% because they were low
quality multi- or duplicate- reads (see above for definition). Thirty eight subjects were
excluded because <15 million reads remained after all QC and another three subjects were
excluded because they withdrew their consent during the study. This left a sample of 1459
subjects with on average 32.4 million quality controlled reads (SD: 13.7 million). The
percentage of uniquely mapped reads was 85.0%, with remaining reads being high-quality
multireads.
Figure 2 shows the correlations between 73 technical replicates (two technical replicates
with reruns were dropped for the sake of simplicity) used to study duplicate- and multi-
reads. The highest correlations between technical replicates (median: 0.92) were obtained
when high-quality multireads and duplicate-reads were included. These correlations
decreased markedly after excluding high-quality multireads (0.80), and decreased modestly
after excluding high-quality duplicate-reads (0.91). Thus, these results supported the
inclusion of both high-quality multi-and duplicate-reads, where the multireads are most
critical. We also dichotomized the methylation measures using ‘non-CpG’ coverage (see the
‘Case–control association testing’ section) and calculated concordance rates. This would, for
example, reduce possible effects of multireads aligning to the same location in the replicates
or outliers. Results in Supplementary Figure 2 show the same pattern as for the correlations
with the inclusion of high-quality multireads improving concordance rates between technical
replicates.
To obtain an indication of the efficiency of the enrichment protocol, we compared the
coverage estimates of the autosomal CpGs with ‘noise’ coverage levels estimated for loci
that were at least 400 bp away from the nearest CpG. The ratio of the median coverage of
CpG versus non-CpG coverage was 40.6. Because for samples that are not enriched the
expected ratio is one, this suggested the enrichment worked properly. Next, for each CpG
we calculated the local CpG density (also called coupling factors [39]) by counting all other
CpGs within ± 100 bp. Figure 3 confirms the well known relation between coverage and
local CpG density [39,48]. The relationship is the result of multiple phenomena such as
different MBD2 binding efficiencies and regions of higher CpG densities being less likely to
be methylated. Isolated CpGs seem relatively difficult to capture using MBD-seq, while
very dense regions (e.g., 40 CpGs within 200 bp) are relatively easy. For optimal
methylome-wide coverage it is important that fragments cover the vast majority of CpGs.
Figure 3 therefore also depicts the relative frequencies (black vertical lines) of CpGs with a
certain density. These frequencies show that the vast majority of CpGs have local densities
in the 1–10 range. As the majority of sequenced fragments also cover CpGs in this range,
this suggests that our MBD protocol provided relatively good coverage of the regions where
most of the CpGs are located.
Results from our in silico alignment experiment indicated that, except for 23 reads, all 2.86
billion reads aligned back to the reference genome. The distribution of the in silico CpG
coverage in Figure 4 shows that the alignment worked well for the majority of CpGs. A total
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of 36% (10.5 million) of the CpGs showed alignment problems (defined as ±10 the expected
coverage of 50). The majority of these CpGs (71.8%) were located in regions flagged as
repetitive elements by RepeatMasker. Alignment problems were highly dependent on the
repeat class with, for example, DNA transposons aligning well and long interspersed nuclear
elements aligning poorly. However, of the 15.0 million CpGs located in repeats, only 50.2%
showed alignment problems. Thus, although repeats are a major source of alignment
problems and CpGs in problematic repeats need to be eliminated, a considerable number of
CpGs in repeats align well and can be retained for subsequent association analyses.
Prior to combining intercorrelated coverage estimates at adjacent sites, we eliminated all
sites with alignment problems. In addition, sites with low coverage were eliminated to avoid
numerical problems when calculating correlations between adjacent CpGs. The remaining
15.6 million CpGs could be combined into 8,822,240 stage 1 blocks, and these stage 1
blocks could in turn be combined into 5,074,538 stage 2 blocks. These results imply overall
data reduction of 67.3% where only 10.9% of the stage 2 blocks consisted of a single CpG.
Table 1 shows that the stage 1 blocks were small (mean = 15.6 bp) with high
intercorrelations (r = 0.95) indicating they indeed involved CpGs in close proximity that
were most likely covered by the same fragments. The stage 2 blocks comprised, on average,
3.1 CpGs with the largest blocks consisting of >18 CpGs and spanning over 500 bp. This
indicated longer range biological correlations between the methylation levels of CpGs.
Figure 5 shows how the sizes of the stage 2 blocks vary across biological features. There is a
clear trend where blocks are larger compared with the methylome-wide average in the
majority of the annotated features. In particular, blocks are larger in CpG islands and shores,
exons, and in UTRs with 5′-UTRs on average being larger than 3′-UTRs. The smallest
average blocks were observed in introns and in regions overlapping with well aligning
repeats.
Association testing & replication
To minimize the probability of false-positive findings due to sites that may not be
methylated, a total of 730,522 stage 2 blocks were excluded because the mean coverage
level was less than the coverage of the 99th percentile of non-CpGs (see the ‘Case–control
association testing’ section). This left 4,344,016 blocks for the MWAS where the mean
number of fragments covering these blocks was 12.9 (SD: 454.3).
In Table 2 we present correlations between the first ten PCs and clinical, demographic and
ancestral dimensions (the intercorrelations among these variables are given in
Supplementary Table 1). In general, correlations were very modest suggesting that most of
the variation in the methylome cannot be attributed to these variables. Four PCs showed
small but significant correlations with case–control status. A number of PCs were correlated
with potential confounders such as smoking and alcohol use. Among the 20 correlations,
only two were significant for the MDS dimensions, suggesting that ancestry did not
substantially contribute to variation in the methylome. As SNP data was missing for 20% of
the sample and their use as covariates would reduce sample size and statistical power, they
were not included in the MWAS.
Based on a scree test (Supplementary Figure 3), we selected the first seven PCs for inclusion
in the association analyses. Prior to the inclusion of the PCs, the quantile–quantile plot
showed considerable inflation (Supplementary Figure 4A: λ = 7.32). This inflation was
effectively dealt with by regressing out the PCs (Supplementary Figure 4B: λ = 1.12).
To study the ability of MBD-seq to identify sites that can be replicated in independent
samples with a technology that provides single base resolution, we designed targeted
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pyrosequencing assays (see Supplementary Table 2 for assay designs) to replicate two of the
top findings from the MWAS where we did not regress out the PCs and also a negative
control. The substantive results and replication findings from the MWAS after regressing
out the PCs will be reported in a separate paper. The two genes were FNDC3B (p < 1.7 ×
10−12) and DCTN (p < 7.8 × 10−13). The replication was carried out in independent samples
from the same study population as the MWAS samples. In these analyses we regressed out
sex and age as well as possible plate effects. Supplementary Figure 5 shows the raw data.
Table 3 summarizes results and shows that the two replication sites comprised a total of five
CpGs that replicated with p-values between 8.5 × 10−4 and 6.2 × 10−3. In addition, the
direction of effects in the MBD-seq and replication study was identical. Cohen’s d [49],
indicated that the case–control difference in the replication study was about half the standard
deviation, which may be considered a medium effect size according to Cohen’s criteria. The
negative control was not significant. Overall, these findings suggested that MBD-seq
identified effects that could be replicated using a technology that provides single base
resolution.
The replication also suggested that association findings obtained if PCs are not regressed out
may reflect real differences between cases and controls and are not type I errors or
technology driven artifacts. To further study possible confounders captured by the PCs, we
ran an MWAS where we regressed out all PCs in the top 30 that were associated with
schizophrenia except the three PCs (1, 4 and 7) that were among the seven main PCs
selected based on the scree test. The top finding in this analysis with a p-value of 1.5 × 10−12
was HTRA3. HTRA3 is known to be hyper-methylated in smokers and this effect can be
demonstrated empirically in cell lines following cigarette smoke carcinogen treatment [50].
It is well established that patients with schizophrenia have an extremely high prevalence of
smoking [51] so this finding is likely the result of the confounding effects of smoking.
Similarly, another top finding is that CAMK2D (p < 1.5 × 10−12) has been suggested in a
large GWAS meta-analysis as a susceptibility gene for metabolic syndrome [52], a well-
known side effect of antipsychotics used to treat schizophrenia.
Epigenetic changes, including DNA methylation, have emerged as key contributors to the
genomic alterations that accompany aging [53]. As several studies of age-related changes in
methylation exist, this outcome provides another opportunity to examine the ability of
MBD-seq to detect associations. To make the most appropriate comparisons, we limit
ourselves to comparisons between our control sample (n = 750) and published exploratory
studies in healthy adult samples. Three such studies used the Illumina Infinium arrays
enabling association testing of 27K sites [54–56]. Among the most robust associations
across these studies involved GRIA2. This gene was one of five loci consistently found to be
hypermethylated with age in several different tissue types in a study by Koch et al. [54],
with a mean correlation of GRIA2 methylation with age across tissues of 0.62. GRIA2 was
also associated with age in the study by Bell et al. [56] using whole blood DNA (p = 4.66 ×
10−6), and was among the top findings (p = 1.37 × 10−6) in a study by Bocklandt et al. [55]
using buccal DNA. In our MWAS for age, GRIA2 was among the top 20 most significant
blocks that reached methylome-wide significance (p-value = 2.78 × 10−8). This validated the
use of MBD-seq to detect association through MWAS.
Discussion
We have tested and validated the use of MBD-seq as a screening tool for MWAS. This
method has the advantages of being cost effective compared with whole-genome bisulfite
shotgun sequencing and, compared with methods based on enzymatic digestion, capable of
assessing methylation levels across the vast majority of sites in the genome. Using a
schizophrenia case–control sample of 1500 subjects, we show that we can replicate top
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findings from the MWAS in independent samples using a different technology that provides
single base resolution. Through an MWAS of age-related methylation changes we were also
able to detect a previously reported robust association involving GRIA2. This supported the
potential of MBD-seq as a cost-effective tool in large-scale methylome-wide disease
association studies.
Repetitive elements constitute approximately 45% of the human genome. Reads may be
difficult to align to these loci because of their high sequence similarity. The methylation of
repeats may be biologically meaningful. For example, transposable elements may be
methylated to prevent them from copying and reinserting, thereby causing possible
disruptions to functional genes. Indeed, methylation markers in repeats have been found to
be associated with diseases [57–59]. Rather than simply eliminating all repeats, we used an
in silico alignment study to discard only those reads with alignment problems. Results
showed that reads mapped well to approximately 50% of the CpGs overlapping with repeats
in RepeatMasker. We also observed alignment problems for 30% of the CpGs that were not
in repeats. These findings suggest that simply excluding all CpGs in repeats may not be an
optimal solution because of the loss of information and the fact that it does not solve all
alignment problems.
Approximately 57.5% of the stage one blocks could be combined into stage two blocks. This
suggested that larger regions of the genome can be similarly methylated, possibly indicating
coordinated epigenetic regulation of gene expression. Consistent with prior observations, we
found that block sizes were larger in CpG dense regions such as island and shores. A
possible explanation [43] may be that above a critical CpG density, neighboring CpGs may
influence each other’s DNA methylation states so that individual CpGs cannot stably
maintain different states. From a biological perspective, this may serve as a bistable
epigenetic switch, in which multiple CpGs collectively maintain a CpG-island-wide ‘on’ or
‘off ’ state. The possible technological implication of this observation is that the single base
resolution offered by bisulfite sequencing may be less critical in CpG dense regions. That is
because if CpG sites have very similar methylation status, it may not be possible to more
precisely locate association signals.
To study how to best handle multireads (reads that align to multiple loci with equal or
similar numbers of mismatches) and duplicate-reads (reads starting at the same base), we
compared different read QC strategies. The use of particularly high-quality multireads
improved data quality. This finding was robust. For example, after dichotomizing (e.g., this
would eliminate possible outlier effects) the methylation measures, we observed the same
pattern where the inclusion of high-quality multireads improved concordance rates between
technical replicates. In addition, two other studies arrived at the same conclusion but
examined the value of multireads in a different context for other outcome measures [41]
[Van den Oord E, Bukszar J, Rudolf G et al. Estimation of CpG coverage in whole
methylome next-generation sequencing studies (2012), Submitted]. Two additional points
are worth noting. First, the majority of multi- and duplicate-reads were deleted and only a
limited set of high-quality reads was retained. For example, there were several areas where
high numbers of duplicate-reads mapped to heterochromatin and pericentromeric regions
that are rich in satellite DNA and other repeats. An explanation is that centromeric DNA
from the physical DNA template is pulled down and sequenced. However, because the
reference genome is only representative of the euchromatic portion, these sequences that are
in very high copy numbers in the sample align to the few sites in the reference genome
where they are represented. Clearly, such reads should be eliminated prior to association
testing. Second, to account for the uncertainty that you do not know from which part of the
genome the multiread comes, we essentially use a simple probability estimate that the read
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aligns to that specific locus. Thus, multireads are treated differently compared with reads
with a single best alignment.
Previous studies have suggested that 30–60 million sequenced reads per sample may be
sufficient to reveal valuable information for whole-genome methylation analysis [30,40].
We obtained on average 68.0 million reads per sample, which is at the high end of these
estimates. After stringent QC, 32.4 million high-quality reads (47.6%) per sample remained.
The association analyses we performed on the block data where, after QC, an average of
12.9 reads covered each block. This appeared sufficient to detect methylation markers that
replicated in independent samples or previously reported associations from age-related
methylation studies. In studies aimed at calling DNA sequence variants the number of
sequenced bases covering the target is the main determinant of accuracy. By contrast, in
MBD-seq studies the number of fragments sequenced is critical because the number of
fragments covering the site is used as a measure of methylation. Factors such as read length
or the use of single- versus paired-end libraries are important in the sense that they improve
the accuracy of the alignment. However, because the number of fragments sequenced
remains unchanged, they are less critical. This has implications for the design of MBD-seq
studies. Rather than increasing read length or using paired-end libraries that are more
expensive and almost double the sequencing run time, it may be more efficient to maximize
the number of fragments sequenced by using single-end libraries and relatively short reads.
MBD-seq has the critical advantage of being cost-effective compared with whole-genome
bisulfite sequencing and even arrays. The method, however, does not provide single base
resolution. Since replication is standard in high dimensional biological investigations, an
obvious approach is to first use MBD-seq to screen for regions of interest and then use a
technology that does provide single base resolution in the replication stage. Our results
provided a proof-of-concept by showing that effects identified with MBD-seq could be
replicated using a technology that provided single base resolution. In this study we used
pyrosequencing for this replication. However, in principle custom array based approaches as
well as approaches using targeted capture of regions of interest followed by bisulfite
sequencing are becoming possible as well.
MBD-seq is semiquantitative in the sense that it does not yield direct estimates of
methylation levels. For the purpose of assessing methylation levels of sites, methods have
been developed to remedy this problem by normalizing the data based on CpG density [39].
These methods are, however, less relevant for MWAS where we focus on a mean difference
between cases and controls. As this mean difference remains unchanged after such
normalization (i.e., for each site a similar constant is added for cases and controls), these
methods will not alter results. Because each site is (one average) covered by multiple reads
MBD-seq is quantitative in the sense that some subjects will have zero reads covering a CpG
and other subjects may have many (e.g., ‘Scores’ could range from, for example, 0–20). As
there is extensive literature showing that dichotomizing quantitative variables may result in
a substantial loss of statistical power [60], it seems better to analyze the data as a
quantitative variable rather than as a binary variable, where data is transformed to
methylation versus no methylation.
Prior to regressing out PCs, λ (the observed median test statistic value divided by the
expected median assuming no effect for any site) was 7.32. We were able to replicate these
pre-PCA findings in independent samples using a different technology. This suggests that
these significant results were not sampling fluctuations or technical artifacts but more likely
caused by the many possible differences between cases and controls (e.g., lifestyle, diet and
medication use) that affect the methylome. We have seen similar dramatic effects previously
when studying the methylation pattern in blood from mice treated with the antipsychotic
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haloperidol [Aberg K, Xie L, McClay J et al. A next-generation sequencing study to
compare genome-wide methylation patterns in whole blood and brain (2012), Submitted]. In
methylation studies where a limited number of sites are assayed (e.g., studying specific
candidate genes), controlling for confounders using PCA or related tools is not possible. An
implication is that such (candidate gene) methylation studies are at high risk for producing
false discoveries. Some caution seems to be required when using tools such as PCA. If
confounders can have such pervasive effects on the methylome, the pathogenic pathways
that cause the disease may also affect many methylation sites. A careful inspection of the
loadings generated by the PCA may be important to identify possible disease pathways and
prevent such components from being regressed out in the MWAS.
The fact that we observed many effects and could replicate the two top findings with smaller
samples sizes seems to suggest, that in MWAS, the challenge may not be to identify
replicable effects but rather to identify those effects, among the many, that are biologically
meaningful for the disease that is being studied. Data integration may be among the tools
that could prove valuable to parse biologically meaningful effects. For example,
confounders cannot affect sequence variation and, with proper control for population
stratification, the direction of effects in GWAS is always from the SNP to the outcome.
Integrating methylation and GWAS results could be useful because MWAS signals in genes
also implicated by GWAS may be more likely to represent causal disease processes.
Methylation can be tissue specific and analyses are therefore ideally performed in the
relevant disease tissue [8]. However, this may not always be possible. Examples are studies
of psychiatric conditions where most of the pathogenic processes are likely to involve brain
or clinical settings where it is important that biosamples can be collected in a multiobtrusive
fashion. In these situations peripheral tissues such as (whole) blood is typically used as a
surrogate. The use of surrogate tissues seems supported by studies suggesting that tissue-
specific DMRs) [61,62] constitute only a limited proportion of all methylated sites. This can
be explained by three possible reasons. First, peripheral tissues may reveal methylation
marks predating or resulting from the epigenetic reprogramming events affecting germline
and embryogenesis [63–66]. As the epigenetic profile of somatic cells is mitotically
inherited, these epigenetic mutations could potentially be found in multiple tissues. Second,
blood contains cells that may be modified as they circulate through diseased tissues, and can
also include cell-free DNA from those tissues [67]. As such, traces of the aberrant
methylation in disease-targeted regions may be present in blood. Finally, and perhaps most
importantly, environmental influences such as diet, drugs and lifestyle factors, as well as
genetic polymorphisms can change methylation levels [68– 71]. Although these changes
may only have a functional effect in specific tissues, it is very well possible that the changes
themselves are more global and cause similarities in methylation profiles across tissues. For
example, after administering an antipsychotic drug to mice we observed high correlations
between changes in methylation in blood, cortex and hippocampus [Aberg K, Xie L,
McClay J et al. A next-generation sequencing study to compare genome-wide methylation
patterns in whole blood and brain (2012), Submitted]. Interestingly, correlations between
blood and brain versus the two brain tissues were very similar, suggesting that blood can
predict the methylation patterns in a specific brain tissue to a similar degree as another brain
tissue.
As is true for most tissues, blood is a complicated biological system consisting of a variety
of cell types. This heterogeneity creates challenges for whole-methylome studies. For
example, if the methylation status of a CpG differ across the various blood cell types in the
same individual, interindividual differences will be reduced in whole blood as the cell type
differences may average out across subjects. Another example is that diseases may alter the
relative abundance of specific cell types. In the presence of heterogeneity in methylation
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patterns, this will produce differences between cases and controls at many CpG sites.
However, as these case–control differences are related to shifts in the general cell type
population, results for individual CpGs would not provide any specific biological insight
into the disease process. Studying cell types adds costs and labor as whole methylome
assays may need to be performed for each cell type and the cells need to be isolated. To
some extent PCA or related techniques provide a statistical solution to this problem. That is
because cases will have different profiles across many methylation sites, these differences
will show up as a PC. If the PCs are regressed out as covariates in multiple regression
analyses, association results will no longer be confounded by these general cell type
differences.
A wide variety of other existing methods can, in principle, be used to analyze MWAS data
(e.g., to remove batch effects [72]). However, a major practical problem is the size of the
data set. We found, for example, that even calculating simple means and standard deviations
using the R package was problematic. To be able to analyze the data, we needed to create
new software that employs parallel computing, uses a low level programming language for
central processing unit intensive calculations, stores intermediate results to avoid computing
the same statistics multiple times or storing results in working memory, and uses algorithms
specifically designed for high dimensional data (e.g., for the PCA). Thus, efficient analysis
of MWAS data is likely to require tailored computational tools.
Conclusion
Owing to the combination of high costs of sequencing entire genomes and the large numbers
of samples needed to provide adequate statistical power, whole-genome bisulfite sequencing
is not currently economically feasible for disease-association studies. MBD-seq may have
limitations but we demonstrate in this paper that not all limitations are relevant for MWAS
(e.g., difficult to estimate actual methylation levels) and that others (e.g., batch effects) can
be remedied. As only a small proportion of the genome (e.g., CpGs constitute only
approximately 1% of the genome) can be methylated, MBD-seq is very cost effective as it
essentially sequences only this potentially methylated proportion while still providing
comprehensive coverage of the methylome. Furthermore, because short range correlations in
the methylation status of CpGs seem pervasive, in many cases it may not be possible to
improve the resolution obtained with MBD-seq owing to these biological constraints. These
properties make MBD-seq a very efficient screening tool for large-scale methylome-wide
disease studies to identify differentially methylated regions that can then be followed up
with more targeted studies.
Future perspective
Because of the promise of methylation studies and the fact that such studies are possible
using biomaterial that is easy to collect, MWAS are likely to become a standard tool to study
complex diseases. Owing to their cost–effectiveness, affinity-based capture followed by
massively parallel sequencing is likely to become a commonly used method.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Methylation studies are a promising complement to genetic studies of variation
in DNA sequence because methylation may capture additional individual
variation in disease susceptibility, can account for a wide variety of phenomena
that characterize complex diseases, and methylation sites are potential new drug
targets plus have good properties from a translational perspective.
• We studied the use of methyl-CpG binding domain protein-enriched genome
sequencing as a cost-effective screening tool for methylome-wide association
studies (MWAS).
• Because methyl-CpG binding domain protein-enriched genome sequencing has
not yet been applied on a large scale, we first developed and tested a pipeline for
data processing using 1500 schizophrenia cases and controls plus 75 technical
replicates with an average of 68 million reads/sample.
• Optimization of the data analysis pipeline included the use of technical
replicates to optimize quality control for multi- and duplicate-reads, an in silico
experiment to identify CpGs in loci with alignment problems, CpG coverage
calculations based on multiparametric estimates of the fragment size
distribution, a two stage adaptive algorithm to combine data from correlated
adjacent CpG sites and principal component analyses to control for confounders.
• We replicated MWAS findings in independent samples using a different
technology that provided single base resolution.
• In an MWAS of age-related methylation changes one of our top findings was a
previously reported robust association involving GRIA2.
• Our results also suggested that due to the many confounding effects, a
considerable challenge in MWAS is to identify those effects that are informative
about disease processes.
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Figure 1. Overview of the data processing pipeline and key results at each step
FDR: False-discovery rate; MBD-seq: Methyl-CpG binding domain sequencing; MWAS:
Methylome-wide association studies; PC: Principal component; PCA: Principal component
analysis; QC: Quality control; QV: Quality value.
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Correlations calculated for 73 duplicates after different quality control procedures for
duplicate- and multi-reads.
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Figure 3. CpG density versus ‘raw’ coverage
For CpG density a simple ‘coupling’ factor was calculated by counting the number of CpGs
within ±100 bp. The vertical lines indicate the relative frequencies of CpGs with that
specific density.
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Distribution of in silico coverage for CpGs in loci overlapping and not overlapping with
RepeatMasker.
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Figure 5. Size of stage 2 blocks across biological features
The mean, median, SD and 99th percentile for the stage 2 block size, in base pairs, is given
for all blocks included and for blocks overlapping with CpG islands, CpG shores, regions
marker by Rep. Mask, genes, exons, introns, 5′-UTRs, 3′-UTRs, regions within 8 kb
upstream of transcriptional start sites corresponding to potential promoter regions
(promoter) and conserved regions (cons). The percentage of blocks overlapping with the
biological features are given in the legend on the x-axis. Note that a single block can overlap
with multiple biological features.
Rep. Mask: RepeatMasker; SD: Standard deviation.
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